Hematox vs Multiple Myeloma [MM]

Hematox®, a bibliographical databank based on drug-induced blood disorders, was created in 1983 by Michel BIOUR (MD, PhD), and monthly updated in accordance with other bibliographical databases to the analysis of the references cited in the articles. All the published cases for selection and classification were re-evaluated in accordance with criterions usually validated in hematology. 1069 drugs are registered with 15126 corresponding and available references. Anticancer drugs and immunomodulators, well known for their intrinsic hematotoxicity, are not indexed in Hematox.

@Point of Care™ With Cognitive AI is a clinical decision-making mobile platform. Multiple Myeloma @Point of Care™ provides a streamlined clinical decision support tool for clinicians to obtain content when it is needed—enabling better decisions, better outcomes, and better care. With Cognitive AI, clinicians use @Point of Care™ to easily access curated, evidence-based, and disease-specific medical content. Clinicians navigate content by asking voice-enabled natural language questions. With Cognitive AI, confidence-rated answers to efficiently incorporate best treatment options happen more quickly and decisions are made faster to improve patient outcomes at the point of care. Multiple Myeloma @Point of Care™ is designed to: • Support discovery and practice change • Provide relevant, evidence-based disease-specific medical content • Improve patient outcomes at the point of care Features: • Continually updated Multiple Myeloma content • Topics in diagnosis, treatment, and care management developed with expert physician authors • Case studies, videos, and interviews • Access to actionable patient-recorded data • Detailed reference list with access to original sources • Continuing medical education credit (CME/CE) • Surveys and peer polling • Patient education resources to share with patients